

The BiRD

Bringing in the Research Dollars!
Pediatric Grant Funding Opportunity Newsletter



We've curated dozens of COVID-19 related research funding announcements to bring you this special **COVID-19 Bringing in the Research Dollars** edition to highlight some of the most relevant and timely Funding Opportunity Announcements (first section), Notices of Special Interest (second section), and a forecasted opportunity to be on the lookout for (third section). Please remember that our [Pediatric Cores](#) are available to support essential research activities and for Emory based grants, the [Emory Facilities and Resources boilerplate tool](#) provides researchers easy access to the most updated and relevant information to include in grant submissions.

This same COVID-19 funding opportunity information is also available in a spreadsheet format that can be accessed [here](#).

COVID-19 and Emerging Respiratory Viruses Research Award

Purpose: To better understand the pathobiology and clinical implications of SARS-CoV-2 and increase knowledge about the potential emerging threat of other novel respiratory viruses. Applications that address basic, clinical, translational, and population health questions will be considered.

Sponsor: American Lung Association

Due Date: 5/30/2020

Amount: \$100,000 per year, for up to two years

Clinical Trial Award for Emerging Viral Diseases and Respiratory Health

Purpose: Rapid implementation of clinical trials with the potential to have a significant impact in one or more of the published Emerging Viral Diseases focus areas (6) or Respiratory Health focus areas (8), all of which relate to SARS-CoV-2 or COVID-19. Must have direct relevance to military health.

Sponsor: Department of Defense

Due Date: Pre-Application (Letter of Intent): June 8, 2020 at 5:00 PM ET

Amount: Applications are not restricted to a predetermined cost limit. Maximum project period is 4 years.

Investigator-Initiated Research Award for Emerging Viral Diseases and Respiratory Health

Includes any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. Clinical trials not allowed. Projects must relate to one or more of the published Emerging Viral Diseases focus areas (6) or Respiratory Health focus areas (8), all of which relate to SARS-CoV-2 or COVID-19. Must have direct relevance to military health.

Sponsor: Department of Defense

Due Date: Pre-Application (Letter of Intent): May 28, 2020 at 5:00 PM ET

Amount: \$1.6 million direct costs total over 4 years for single PI; \$2 million direct costs total over 4 years with Partnering PI

Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health

Purpose: To translate promising preclinical findings into products for clinical applications in one or more of the published Emerging Viral Diseases focus areas (6) or Respiratory Health focus areas (8), all of which relate to SARS-CoV-2 or COVID-19. This award is product-driven; the product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. Must have direct relevance to military health.

Sponsor: Department of Defense

Due Date: Pre-Application (Letter of Intent): May 28, 2020 at 5:00 PM ET

Amount: Max. \$4 million direct costs total over 4 years

Clinic Testing Therapeutic/Indication Pairing Strategies (U01 Clinical Trial Required) (not limited to COVID-19)

Purpose: To support clinical studies to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase I trial for a different indication by the time an award is made. The U01 award also may be used for Phase I and/or Phase II clinical trials for a new therapeutic use to establish substantial evidence of efficacy and to establish evidence of safety for the new use.

Sponsor: NIH: NCATS

Due Date: Standard NIH Deadlines (new: Feb 5, June 5, Oct 5)

Amount: Maximum \$3 million direct costs/year, up to 3 years

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)

Purpose: To provide an expedited funding mechanism for research on SARS-CoV-2 and/or COVID-19, particularly to improve understanding of fundamental virology, immunology, and the development of animal models, reagents, and medical countermeasures. The R21 activity code is intended to encourage new exploratory and developmental research projects that lack preliminary data.

Sponsor: NIH: NIAID

Due Date: Rolling until April 30, 2021

Amount: Max. \$200,000/year in direct costs and \$275,000/entire project period in direct costs. The total project period may not exceed 2 years.

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)

Purpose: To provide an expedited funding mechanism for research on SARS-CoV-2 and/or COVID-19, particularly to improve understanding of fundamental virology, immunology, and the development of animal models, reagents, and medical countermeasures. The R01 activity code is intended for projects that already have preliminary data and/or may include longitudinal analysis.

Sponsor: NIH: NIAID

Due Date: Rolling until April 30, 2021

Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 5 years.

Rapid Acceleration of Diagnostics (RADx) - Fast-Track Program for COVID-19 Test Development and Distribution

Purpose: To increase US testing capacity for SARS-CoV-2 by 100-fold by accelerating the development, validation, and commercialization of innovative point-of-care and home-based tests, and improvements to clinical laboratory tests. NIBIB will consider innovations at all stages of readiness.

Sponsor: NIH: NIBIB

Due Date: Rolling until further notice; applications will be reviewed within one week of receipt

Amount: \$25k to millions

COVID-19 Targeted PFA (opens May 5, 2020)

Purpose: To (1) strengthen the understanding of different approaches to mitigate the impact of COVID-19 on individuals, communities, healthcare providers, and healthcare systems; and (2) provide evidence to inform clinical and public health responses, decision making, and planning. Preference will be given to projects focused on the following priority areas:

- Adaptations to healthcare delivery
- Impact of COVID-19 on vulnerable populations
- Impact of COVID-19 on healthcare workforce well-being, management, and training

Sponsor: PCORI

Due Date: 5/26/2020

Amount: Small Studies: up to \$2,500,000 — Large Studies: up to \$5,000,000. Maximum project period is 2 years.

Mitigating Risk in the Wake of the COVID-19 Pandemic

For mid-career researchers only; only one candidate per department.

Purpose: To address COVID-19 impact, recovery and preparedness. Applications must relate to at least one of these topics:

- Protecting vulnerable populations from epidemics and catastrophes, including COVID-19
- Improving data collection and quality in health
- Understanding the effects of confinement and social distancing
- Early warning and preparedness
- Preserving the environment and our health

Sponsor: AXA Research Fund

Due Date: May 7, 2020 at 10:00 AM

Amount: Maximum of 250,000€ total for a project period of 1-3 years

Newton Award for Transformative Ideas during the COVID-19 Pandemic

Purpose: To develop a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. Approaches can include analytical reasoning, calculations, simulations, and thought experiments. While the use and production of datasets is allowed, any new supporting data should be generated without the use of any experimentation or instrumentation due to the nation-wide closure of laboratories.

Sponsor: Department of Defense

Due Date: Rolling until May 15, 2020 at 4:00 PM ET

Amount: Total costs (direct plus indirect) will not exceed \$50,000 per investigator or \$100,000 for a collaborative project by two investigators. Project periods are 6 months.

Research Grants

Purpose: To analyze social, political, economic, or psychological disruptions resulting from the coronavirus crisis that affect social and living conditions in the United States. Core program areas and special initiatives: Behavioral Economics; Decision-Making and Human Behavior in Context; Future of Work; Race, Ethnicity, and Immigration; Social, Political, and Economic Inequality.

Sponsor: Russell Sage Foundation

Due Date: Letters of Inquiry (LOIs) due May 21, 2020

Amount: \$35,000 to \$175,000, including up to 15% indirect cost

Rapid Response Research Grants on the Coronavirus Disease 2019 (COVID-19)

Purpose: To conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

Sponsor: National Science Foundation

Due Date: Rolling

Amount: Up to \$200K for up to one year

MP3 Initiative Seed Grants for COVID-19: Second Call for Letters of Intent

Purpose: To facilitate and grow basic and applied infectious disease research across scales at Emory University, from molecules and pathogens within hosts to populations and pandemics. The main way in which the initiative will accomplish this is to provide sizable seed grants to interdisciplinary teams of researchers, to provide proof-of-concept and preliminary results for subsequent applications for research grants, program grants, center grants and training grants.

Sponsor: Emory University

Due Date: 6/5/2020

Amount: \$100k for teams of 2 faculty; \$150k for teams of 3+ plus faculty. Project period of up to one year.

Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)

Purpose: To solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

Sponsor: NIAID

Due Date: June 29, 2020 by 5:00 PM local time

Amount: Recommended budget for direct costs of up to \$750,000 per year may be requested. Applicants may also request up to an additional \$300,000 in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totaling \$1,050,000 direct costs for Year 1 only. Maximum project period 5 years.

Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed)

Purpose: To support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals. Research areas supported by this FOA include immune system development, function or regulation; mechanisms governing immune response to infectious pathogens, vaccines or adjuvants; host susceptibility factors and mechanisms of pathogen-induced immunopathology; and immune mechanisms involved in the development and progression of immune-mediated diseases, such as allergy/asthma, autoimmunity, primary immunodeficiency, inflammation, and cell/organ/tissue transplant rejection or tolerance.

Sponsor: NIAID

Due Date: September 4, 2018, September 3, 2019, and September 9, 2020 , by 5:00 PM local time

Amount: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The total project period may not exceed 2 years.

Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) - Rapid Response Research (RAPID) Funding Mechanism

The National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

Sponsor: NSF

Due Date: Rolling

Amount: Up to \$200K and up to one year in duration

Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

BARDA will only accept submissions related to the SARS-CoV-2 virus or the COVID-19 disease until further notice. Offerors may include single entities or teams from private sector organizations, government laboratories, and academic institutions.

Sponsor: BARDA

Due Date: 10/31/2020

Amount: Not specified

Biomedical Advanced Research and Development Authority (BARDA) Easy Broad Agency Announcement

Several COVID-19-related topics added, including:

- Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus
- Diagnostic Tests for detection of COVID-19 disease
- Remote Patient Monitoring and Diagnostic Tools
- Vaccines
- Advanced Manufacturing Technologies

Sponsor: BARDA's Division of Research, Innovation & Ventures (DRIVE)

Due Date: Jun 30, 2020 by 5:00 pm EST

Amount: Less than \$750,000 total

Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)

Purpose: To support milestone-driven preclinical research that will advance the development and/or production of lead candidate therapeutics or vaccines (or related products) for select Emerging Infectious Diseases/Pathogens.

Sponsor: NIAID

Due Date: Jun 29, 2020 by 5:00 pm local time

Amount: Recommended budget for direct costs of up to \$750,000 per year may be requested. Applicants may also request up to an additional \$300,000 in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totaling \$1,050,000 direct costs for Year 1 only. The maximum project period is 5 years.

Notices of Special Interest, Administrative Supplements & Urgent Competitive Revisions (Scope and Deadlines Vary)

NIH Parent Announcements

Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

Purpose: To provide funds for NIH grantees to expand the scope of their active grant.

FOA or Notice #: PA-20-135

Sponsor: NIH

Due Date: Varies

Amount: Varies

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Purpose: To provide additional funds for NIH grantees for work that falls within the scope of their active grant.

FOA or Notice #: PA-18-591

Sponsor: NIH

Due Date: Varies

Amount: Varies

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner.

FOA or Notice #: PA-18-935

Sponsor: NIH

Due Date: Varies

Amount: Varies

Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional)

For grantees holding active AHRQ awards (except R13s, T32s, F32s), for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis.

FOA or Notice #: PA-20-070

Sponsor: ARHQ

Due Date: May 29, 2020 by 5:00 PM local time

Amount: Varies

[Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research \(PCOR\) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 \(Supplement - Clinical Trial Optional\)](#)

For grantees holding active AHRQ awards that were funded under the PCOR FOAs to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis.

FOA or Notice #: PA-20-072

Sponsor: ARHQ

Due Date: May 29, 2020 by 5:00 PM local time

Amount: Varies

Institute Specific

[NOSI: Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 \(COVID-19\)](#)

FOA or Notice #: NOT-CA-20-042

Sponsor: NCI

[Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System](#)

FOA or Notice #: NOT-NS-20-051

Sponsor: NINDS

[Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 \(COVID-19\) for Currently Active NHLBI Phase I-III Clinical Trials](#)

FOA or Notice #: NOT-HL-20-782

Sponsor: NHLBI

[Data Driven Research on Coronavirus Disease 2019 \(COVID-19\)_\(R21\)](#)

FOA or Notice #: NOT-LM-20-011

Sponsor: NLM

[Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 \(SARS-CoV-2\) and Coronavirus Disease 2019 \(COVID-19\)](#)

FOA or Notice #: NOT-RM-20-015

Sponsor: Office of Strategic Coordination (Common Fund)

[NOSI: Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease \(COVID-19\)](#)

FOA or Notice #: NOT-TR-20-012
Sponsor: NCATS

[NOSI regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus](#)

FOA or Notice #: NOT-MH-20-047
Sponsor: NIMH, NIA, NIAAA, NIMHD

[NOSI: Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities](#)

FOA or Notice #: NOT-MD-20-019
Sponsor: NIMH, NIA, NIMHD

[NOSI\): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 \(COVID-19\)](#)

FOA or Notice #: NOT-AT-20-011
Sponsor: NCCIH, NIA, NIAAA

[NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 \(COVID-19\)](#)

FOA or Notice #: NOT-DC-20-004
Sponsor: NIDCD

[NOSI: Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 \(COVID-19\) within the Mission of NIDDK](#)

FOA or Notice #: NOT-DK-20-018
Sponsor: NIDDK

[NOSI: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 \(COVID-19\) within the Mission of NIAAA](#)

FOA or Notice #: NOT-AA-20-011
Sponsor: NIAAA

[NOSI: Availability of Administrative Supplements for Research on Coronavirus Disease 2019 \(COVID-19\)](#)

FOA or Notice #: NOT-LM-20-010
Sponsor: NLM

NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)

FOA or Notice #: NOT-ES-20-017
Sponsor: NIEHS

NOSI: Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

FOA or Notice #: NOT-AI-20-034
Sponsor: NIAID

NOSI: Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

FOA or Notice #: NOT-HG-20-030
Sponsor: NHGRI

NOSI: Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

FOA or Notice #: NOT-HL-20-757
Sponsor: NHLBI

NOSI: Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

FOA or Notice #: NOT-EB-20-007
Sponsor: NIBIB

NOSI: NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

FOA or Notice #: NOT-AG-20-022
Sponsor: NIA, NIMH, NIAAA

NOSI: Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

FOA or Notice #: NOT-GM-20-025
Sponsor: NIGMS

NOSI: Clinical and Translational Science Award (CTSA) Program

Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need

FOA or Notice #: NOT-TR-20-011

Sponsor: NCATS

Notice of National Institute of Dental and Craniofacial Research (NIDCR) Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

FOA or Notice #: NOT-DE-20-020

Sponsor: NIDCR, NHGRI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDCR, NIDDK, NIDA, NIEHS, NIMH, NIMHD, NCI

Forecasted

Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19

Prepare to submit applications to AHRQ to fund critical research focused on evaluating topics such as innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic.

Sponsor: Agency for Healthcare Research and Quality (AHRQ)